Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

About Hydronidone (F351) F351 is a structural analogue of the approved anti-fibrotic drug ... pulmonary fibrosis) and has been shown to inhibit in vitro both p38γ kinase activity and TGF-β1 ...

F351 is a structural analogue of the approved anti-fibrotic drug Pirfenidone (approved in the PRC for the treatment of idiopathic pulmonary fibrosis) and has been shown to inhibit in vitro both p38?

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) and keeping the ...

The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and ...

1 State Key Laboratory Cell Differentiation and Regulation, Henan International Joint Laboratory of Pulmonary ... of hepatic fibrosis is linked to chronic viral hepatitis, alcohol abuse, fatty liver ...

Thomas H. Sisson, Toby M. Maher, Iyabode O. Ajayi, Jessie E. King, Peter D.R. Higgins, Adam J. Booth, Rommel L. Sagana, Steven K. Huang, Eric S. White, Bethany B ...

MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...